Transcript Jonathan Pearce Presentation

MRC Stratified Medicine Initiative
Jonathan Pearce
Medical Research Council, Translational Programme Manager
University of Glasgow Industry Day: 24 September 2015
Stratified medicine has the potential to
deliver improved diagnoses and therapies
Input
Tools
Outputs
Affected
population
Disease Strata
Clinical
Presentation
/Phenotype
Genetic /
Molecular
Value
Therapeutic
Response
- Diagnostics to
better predict
disease state,
prognosis,
response
- Mechanism of
disease leading to
new therapies
Capturing this potential requires true partnership between basic and clinical
researchers, industry (BioPharma and Diagnostics) and patients. No one group
has all the necessary skills/resources
1
… and partnership between funders,
regulators, evaluators and providers
Stratified Medicine
Innovation Platform
Programme Coordination
Group
2
MRC Stratified Medicine Initiative
• Set up in 2010/11 and represented a new way of
funding from the MRC
• Builds on the MRC/ABPI Inflammation and Immunology
(I&I) Initiative
• £60m initiative to develop disease-specific research
consortia, involving industry partners
• Consortia exploring predictors of response and
mechanisms underpinning disease stratification, where
there is evidence that therapeutically relevant strata
exist
3
MRC Stratified Medicine Consortia
RASP-UK
PSORT
MATURA-II
MASTERPLANS
• 13 internationally
competitive stratified
medicine discovery
engines
• Build on NIHR and
DA clinical research
UKPBC
funding
• Total investment c.
RAMAP-II
£57m
• 3 charity co-funders
COPDMAP
(CRUK, ARUK, BHF)
GAUCHERITE • 32 academic and 51
commercial partners
MATURA-I
S-CORT
AIM HY
MASTERMIND
STOP-HCV
STRATA
RAMAP-I
Auto-Immune
Mental Health
Respiratory
Cardiovascular
Cancer
Congenital
Infections
Diabetes
STOP-HCV – 21 Partners; 12 Academic, 8
Industrial, 1 Governmental and Patient
Stratified medicine relies on an ability to
integrate and interrogate multi-level data
• In last 2 years (2012-2014) MRC has invested over
£100m in informatics infrastructure and capabilities
24 academic institutions
2 MRC Units
CIPHER
London
HeRC
Scotland
Medical Bioinformatics
Leeds
Imperial
Oxford
UCL/Crick
Uganda
Warwick/Swansea
6
Molecular pathology review
• If the UK is to capture the
stratified medicine opportunity,
we need to be able to translate
both its therapeutic and
diagnostic outputs to patient
and economic benefit
• While much consideration has
been given to the challenges
faced by those developing new
therapies, less work has
focused on the needs of
diagnostics
• MRC has undertaken a review
focused on these needs
7
Review recommendations
• Path - Produce clear unified guidance setting out the critical
path and required evidence for the discovery, development,
approval and evaluation of tests. Address the gaps in the UK’s
regulatory, evaluation, adoption and delivery system
• Proximity - Establish joint research/clinical service ‘nodes’
aligned with industry and complementing NIHR, TSB and
other RC and partner investments
• People • Train next generation of research leaders in molecular pathology,
potential merit of guaranteed follow through clinical lectureships
• Further development of UK capacity in statistics, bioinformatics
and health economics
• Undergraduate medical curriculum to include molecular
pathology, to aid adoption and interpretation
8
MRC and EPSRC molecular pathology
nodes call
• In an initial response to recommendations, the MRC and
EPSRC have launched a joint call to support up to eight
molecular pathology nodes
• Up to £17.5m (£15m from MRC and £2.5m from EPSRC)
• Each node will be a multidisciplinary centre of innovative
molecular diagnostic test discovery and development
bringing together:
• the research base
• pathology/genetic services and
• industry
9
MRC Stratified Medicine Consortia and
MRC EPSRC Molecular Pathology Nodes
•
13 internationally
competitive stratified
medicine discovery engines
•
•
Edinburgh/
St Andrews
Glasgow
RASP-UK
•
Newcastle
UKPBC
•
RAMAP-II
PSORT
MATURA-II
Nottingham
6 centres of innovative
molecular diagnostic test
development
COPDMAP
Manchester
Leicester/
Loughborough
MASTERPLANS
GAUCHERITE
MATURA-I
S-CORT
AIM HY
MASTERMIND
STOP-HCV
STRATA
RAMAP-I
Total c. £60m
3 charity co-funders (CRUK,
ARUK, BHF)
32 academic and 51
commercial partners
•
•
Total c. £16m
8 academic and 21
commercial partners
Auto-Immune
Mental Health
Respiratory
Cardiovascular
Cancer
Congenital
Infections
Diabetes
Node
The nodes will work as a network and
complement partner investments
Discovery Science/
Early TRL
Mid TRL
MRC Stratified
Medicine
Consortia
Science
base
Late TRL
NIHR
DECs
Nodes
Precision
Medicine
Catapult
NHS
EPSRC
Analytical
Sciences
RC Centres
Discovery
MHRA
NIHR BRCs/BRUs
GEL
Validation
Regulation
NICE
NHS Innovation
Evaluation
Adoption